<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03258931</url>
  </required_header>
  <id_info>
    <org_study_id>ARO-021</org_study_id>
    <nct_id>NCT03258931</nct_id>
  </id_info>
  <brief_title>Study of Crenolanib vs Midostaurin Following Induction Chemotherapy and Consolidation Therapy in Newly Diagnosed FLT3 Mutated AML</brief_title>
  <official_title>Phase III Randomized Study of Crenolanib Versus Midostaurin Administered Following Induction Chemotherapy and Consolidation Therapy in Newly Diagnosed Subjects With FLT3 Mutated Acute Myeloid Leukemia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Arog Pharmaceuticals, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Arog Pharmaceuticals, Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      A phase III randomized multi-center study designed to compare the efficacy of crenolanib with
      that of midostaurin when administered following induction chemotherapy, consolidation
      chemotherapy and bone marrow transplantation in newly diagnosed AML subjects with FLT3
      mutation. About 510 subjects will be randomized in a 1:1 ratio to receive either crenolanib
      in addition to standard first line treatment of AML (chemotherapy and if eligible,
      transplantation) (arm A) or midostaurin and standard treatment (arm B). Potentially eligible
      subjects will be registered and tested for the presence of FLT3 mutation. Once the FLT3
      mutation status is confirmed and additional eligibility is established, subject will be
      randomized and enter into the treatment phase.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">May 2018</start_date>
  <completion_date type="Anticipated">November 2024</completion_date>
  <primary_completion_date type="Anticipated">November 2022</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Event-free survival (EFS)</measure>
    <time_frame>5 years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall Survival</measure>
    <time_frame>7 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Relapse free survival</measure>
    <time_frame>5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Composite complete remission rate</measure>
    <time_frame>5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of response</measure>
    <time_frame>5 years</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">510</enrollment>
  <condition>Newly Diagnosed FLT3 Mutated AML</condition>
  <arm_group>
    <arm_group_label>Crenolanib</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Crenolanib following salvage chemotherapy</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Midostaurin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Midostaurin following salvage chemotherapy</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Crenolanib</intervention_name>
    <description>Crenolanib will be administered orally</description>
    <arm_group_label>Crenolanib</arm_group_label>
    <other_name>Crenolanib besylate</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Midostaurin</intervention_name>
    <description>Midostaurin will be administered orally</description>
    <arm_group_label>Midostaurin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cytarabine</intervention_name>
    <description>100 mg/m² IV continuous infusion over 24 hours</description>
    <arm_group_label>Crenolanib</arm_group_label>
    <arm_group_label>Midostaurin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Duanorubicin</intervention_name>
    <description>90 mg/m2 IV</description>
    <arm_group_label>Crenolanib</arm_group_label>
    <arm_group_label>Midostaurin</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Confirmed diagnosis of de novo AML according to World Health Organization (WHO) 2016
             classification

          -  Presence of FLT3-ITD and/or D835 mutation(s) in bone marrow or peripheral blood

          -  Age ≥ 18 years and ≤ 60 years

          -  Adequate hepatic function within 48 hours prior to induction chemotherapy

          -  Adequate renal functions within 48 hours prior to induction chemotherapy

          -  ECOG performance status within 48 hours prior to induction chemotherapy ≤ 3

          -  Eligible for intensive cytarabine/daunorubicin (7+3) chemotherapy specified

        Exclusion Criteria:

          -  Acute promyelocytic leukemia (APL)

          -  Known clinically active central nervous system (CNS) leukemia

          -  Severe liver disease

          -  Active infections

          -  Known, active infection with hepatitis B virus (HBV) or hepatitis C virus (HCV)

          -  Known infection with human immunodeficiency virus (HIV)

          -  Prior systemic anti-cancer treatment (e.g. chemotherapy, tyrosine kinase inhibitors,
             immunotherapy, or investigational agents)(except for hydroxyurea and/or leukapheresis)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <verification_date>January 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 21, 2017</study_first_submitted>
  <study_first_submitted_qc>August 21, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">August 23, 2017</study_first_posted>
  <last_update_submitted>January 16, 2018</last_update_submitted>
  <last_update_submitted_qc>January 16, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">January 18, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cytarabine</mesh_term>
    <mesh_term>Midostaurin</mesh_term>
    <mesh_term>Crenolanib</mesh_term>
    <mesh_term>Staurosporine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

